[On the therapy of muscular diseases].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D045930:Anabolic Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003882:Dermatomyositis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists; D009135:Muscular Diseases / Q000188:drug therapy* / Q000628:therapy; D009136:Muscular Dystrophies / Q000188:drug therapy; D009157:Myasthenia Gravis / Q000188:drug therapy; D009220:Myositis / Q000188:drug therapy; D009388:Neostigmine / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D045930:Anabolic Agents; D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents; D000451:Mineralocorticoid Receptor Antagonists; D014810:Vitamin E; D009388:Neostigmine; D011729:Pyridostigmine Bromide
Zur Therapie der Muskelkrankheiten.